GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sprint Bioscience AB (OSTO:SPRINT) » Definitions » EV-to-EBITDA

Sprint Bioscience AB (OSTO:SPRINT) EV-to-EBITDA : 8.61 (As of Jun. 19, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sprint Bioscience AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sprint Bioscience AB's enterprise value is kr62.33 Mil. Sprint Bioscience AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr7.24 Mil. Therefore, Sprint Bioscience AB's EV-to-EBITDA for today is 8.61.

The historical rank and industry rank for Sprint Bioscience AB's EV-to-EBITDA or its related term are showing as below:

OSTO:SPRINT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2762.77   Med: -3.4   Max: 210.11
Current: 8.61

During the past 13 years, the highest EV-to-EBITDA of Sprint Bioscience AB was 210.11. The lowest was -2762.77. And the median was -3.40.

OSTO:SPRINT's EV-to-EBITDA is ranked better than
50% of 456 companies
in the Biotechnology industry
Industry Median: 8.71 vs OSTO:SPRINT: 8.61

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-19), Sprint Bioscience AB's stock price is kr1.464. Sprint Bioscience AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.120. Therefore, Sprint Bioscience AB's PE Ratio for today is 12.20.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Sprint Bioscience AB EV-to-EBITDA Historical Data

The historical data trend for Sprint Bioscience AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sprint Bioscience AB EV-to-EBITDA Chart

Sprint Bioscience AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.26 -3.77 -4.97 - -34.23

Sprint Bioscience AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.65 16.91 -34.23 4.42

Competitive Comparison of Sprint Bioscience AB's EV-to-EBITDA

For the Biotechnology subindustry, Sprint Bioscience AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sprint Bioscience AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sprint Bioscience AB's EV-to-EBITDA falls into.



Sprint Bioscience AB EV-to-EBITDA Calculation

Sprint Bioscience AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=62.326/7.238
=8.61

Sprint Bioscience AB's current Enterprise Value is kr62.33 Mil.
Sprint Bioscience AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr7.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sprint Bioscience AB  (OSTO:SPRINT) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sprint Bioscience AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.464/0.120
=12.20

Sprint Bioscience AB's share price for today is kr1.464.
Sprint Bioscience AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.120.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Sprint Bioscience AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sprint Bioscience AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sprint Bioscience AB (OSTO:SPRINT) Business Description

Traded in Other Exchanges
Address
Halsovagen 7, Floor 8, Elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a Sweden based company involved in developing drugs focused on cancer and metabolism. The project portfolio of the company includes STK25, VPS34, and PIP4K2.

Sprint Bioscience AB (OSTO:SPRINT) Headlines

No Headlines